As the majority of especially metastatic NSCLC cancers harbors p53 mutations, the therapeutic use of rotenone–TRAIL combination in p53 null NSCLC cancers may be of great significance. This evidence concerns the gene TNFSF10 and non-small cell lung carcinoma.